Aprea Therapeutics (APRE) Free Cash Flow (2018 - 2026)

Aprea Therapeutics (APRE) has reported Free Cash Flow for 9 consecutive years, with -$2.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow rose 24.08% year-over-year to -$2.8 million; the TTM figure through Mar 2026 stood at -$12.0 million (up 9.35% YoY), while the FY2025 annual figure was -$12.9 million, up 4.99% from the prior year.
• Free Cash Flow climbed to -$2.8 million in Q1 2026 per APRE's latest filing, from -$3.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$2.2 million in Q3 2023 and bottomed at -$8.9 million in Q2 2022.
• Historically, Free Cash Flow has averaged -$3.9 million across 5 years, with a median of -$3.5 million in 2024.
• Annual changes were most pronounced in 2023 — Free Cash Flow soared 65.99% — and 2024, when it tumbled 32.39%.
• Aprea Therapeutics' Free Cash Flow stood at -$4.0 million in 2022, then advanced by 6.81% to -$3.7 million in 2023, then advanced by 6.3% to -$3.5 million in 2024, then rose by 15.65% to -$3.0 million in 2025, then grew by 6.91% to -$2.8 million in 2026.
• Business Quant data shows APRE's Free Cash Flow at -$2.8 million in Q1 2026, -$3.0 million in Q4 2025, and -$3.2 million in Q3 2025.